| Chelsea Therapeutics announced that Horacio Kaufmann, M.D. will present results from Droxidopa Study 302 at the American Autonomic Society's 20th Annual International Symposium on the Autonomic Nervous System in St. Thomas, U.S. Virgin Islands. Preliminary results from Study 302, the first of two pivotal Phase III trials in Chelsea's registration program of Droxidopa for he treatment of symptomatic, neurogenic orthostatic hypotension, were first reported on September 24. :theflyonthewall.com |